Analysts Getting More Bullish On ViroPharma Following Friday's 28+% Surge On Takeover Chatter
ViroPharma (NASDAQ: VPHM) shares are up about three-quarters of a percent Monday morning on the heels of a 28-plus percent move higher on Friday. Traders in the name were responding to chatter the company had received offers from both Sanofi (NYSE: SNY) and Shire (NASDAQ: SHPG).
Monday morning numerous analysts are commenting and raising price targets on ViroPharma.
- Stifel Nicolaus raised target from $41 to $47, Buy rating maintained.
- Piper Jaffray target from $37 to $46, Overweight maintained.
- Oppenheimer target from $35 to $44, Outperform maintained.
- Mizuho sees value of $45 assuming cost savings if M&A does happen, believes could include a contingent value of $2-3/share related to cinryze.
ViroPharma shares last traded at $39.41.
Latest Ratings for VPHM
|Nov 2013||Stifel Nicolaus||Downgrades||Buy||Hold|
|Nov 2013||JP Morgan||Downgrades||Overweight||Neutral|
|Nov 2013||Piper Jaffray||Downgrades||Overweight||Neutral|
© 2014 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.